Features of pharmacotherapy at elderly and senile patients
A. V. Safronenko,
E. V. Gantsgorn,
V. A. Safronenko,
I. I. Kuznetsov,
N. V. Sukhorukova,
A. V. Krishtopa,
A. A. Osipova https://doi.org/10.21886/2712-8156-2021-2-4-6-15
Abstract
The high risk of developing adverse drug reactions (ADRs) among elderly and senile patients is caused several reasons. Firstly, the age‑associated changes organs and system cause certain changes in pharmacodynamics and pharmacokinetics of drugs and, as a consequence, atypical ADRs. Secondly, polymorbidity, which is often present in this category of patients, causes the phenomenon of polypharmacy, thereby exacerbating the aspect of drug‑drug interactions – one of the risk factors for the development of ADRs. Finally, low level of knowledge in this area healthcare practitioners causes reason developing of «pharmacological cascades». The active applying of geriatric pharmacology in clinical practices gives the chance do better live the quality of life and the prediction of diseases for elderly and senile patients.
About the Authors
A. V. Safronenko
Rostov State Medical University
Russian Federation
Russian Federation
Andrey V. Safronenko, Dr. Sci. (Med.), professor, Head of the Department of pharmacology and clinical pharmacology
Rostov-on-Don
E. V. Gantsgorn
Rostov State Medical University
Russian Federation
Russian Federation
Elena V. Gantsgorn, Cand. Sci. (Med.), аssociate professor of the Department of pharmacology and clinical pharmacology
Rostov-on-Don
V. A. Safronenko
Rostov State Medical University
Russian Federation
Russian Federation
Victoria A. Safronenko, Cand. Sci. (Med.), associate professor at the Department of internal diseases no. 1
Rostov-on-Don
I. I. Kuznetsov
Rostov State Medical University
Russian Federation
Russian Federation
Igor I. Kuznetsov, student; general medicine
Rostov-on-Don
N. V. Sukhorukova
Rostov State Medical University
Russian Federation
Russian Federation
Natalya V. Sukhorukova, Cand. Sci. (Med.), аssociate professor of the Department of pharmacology and clinical pharmacology
Rostov-on-Don
A. V. Krishtopa
Rostov State Medical University
Russian Federation
Russian Federation
Anna V. Krishtopa, Cand. Sci. (Med.), аssociate professor of the Department of pharmacology and clinical pharmacology
Rostov-on-Don
A. A. Osipova
Rostov State Medical University
Russian Federation
Russian Federation
Alisa V. Osipova, student; general medicine
Rostov-on-Don
References
1. GBD 2015 Mortality and Causes of Death Collaborators. Global, regional, and national life expectancy, all-cause mortality, and cause-specific mortality for 249 causes of death, 1980-2015: a systematic analysis for the Global Burden of Disease Study 2015. Lancet. 2016;388(10053):1459-1544. DOI: 10.1016/S01406736(16)31012-1. Erratum in: Lancet. 2017;389(10064):e1. PMID: 27733281; PMCID: PMC5388903.
2. Ушкалова Е.А., Ткачева О.Н., Рунихина Н.К., Чухарева Н.А., Бевз А.Ю. Особенности фармакотерапии у пожилых пациентов. Введение в проблему. Рациональная фармакотерапия в кардиологии. 2016;12(1):94-100. DOI: 10.20996/1819-6446-2016-12-1-94-100
3. Сычев Д.А., Остроумова О.Д., Кочетков А.И., Переверзев А.П., Остроумова Т.М., Клепикова М.В. и др. Лекарственно-индуцированные заболевания: эпидемиология и актуальность проблемы. Фарматека. 2020;27(5):77–84. DOI: 10.18565/pharmateca.2020.5.77-84
4. Tisdale J.E., Miller D.A. Drug-induced diseases: prevention, detection, and management. 3rd ed. Bethesda, Md.: American Society of Health-System Pharmacists, 2018.
5. Петров В.И. Гериатрическая фармакология. Вестник Волгоградского государственного медицинского университета. 2011;1(37):3-7. Elibrary ID: 16403672
6. Сычев Д.А. Полипрагмазия в клинической практике: проблема и решения. Учебное пособие. 2-е изд., испр. И доп. Спб, 2018.
7. Franck L., Molyneux N., Parkinson L. Systematic review of interventions addressing social isolation and depression in aged care clients. Qual Life Res. 2016;25(6):1395-1407. DOI: 10.1007/s11136-015-1197-y
8. Belovol A.N., Kazakov I.I. Clinical pharmacology in geriatrics. Medix Anti-aging. 2012;1(25):50-55.
9. Angamo M.T., Chalmers L., Curtain C.M., Bereznicki L.R. Adverse-drug-reaction-related hospitalisations in developed and developing countries: a review of prevalence and contributing factors. Drug Saf. 2016;39(9):847—857. DOI: 10.1007/ s40264016-0444-7
10. Hakkarainen K.M., Gyllensten H., Jönsson A.K., Andersson Sundell K., Petzold M., Hägg S. Prevalence, nature and potential pre-ventability of adverse drug events — a population-based medical record study of 4970 adults. Br J Clin Pharmacol. 2014;78(1):170—183. DOI: 10.1111/bcp.12314
11. Tandon V.R., Khajuria V., Mahajan V., Sharma A., Gillani Z., Mahajan A. Drug-induced diseases (dids): An experience of a tertiary care teaching hospital from India. Indian J Med Res. 2015;142(1):33—39. DOI: 10.4103/0971-5916.162093
12. Hanlon P., Nicholl B., Jani B.D., Lee D., mcqueenie R. Frailty and pre-frailty in middle-aged and older adults and its association with multimorbidity and mortality: a prospective analysis of 493 737 UK Biobank participants. The Lancet Public Health. 2018;3(7):e323-e332. DOI: 10.1016/S24682667(18)30091-4
13. Duerden M., Payne R. Polypharmacy – what is it and how common is it? Prescriber. 2014;25(21):44-47.
14. Beijer H.J., de Blaey C.J. Hospitalisati caused by adverse drug reactions (ADR): a meta-analysis of observational studies. Pharm World Sci. 2002;24(2):46-54. DOI: 10.1023/a:1015570104121.
15. National Institute for Health and Care Excellence. Multimorbidity: clinical assessment and management (NICE Guideline 56), 2016.
16. Held FP, Blyth F, Gnjidic D, Hirani V, Naganathan V, Waite LM, et al. Association Rules Analysis of Comorbidity and Multimorbidity: The Concord Health and Aging in Men Project. J Gerontol A Biol Sci Med Sci. 2016;71(5):625-31. DOI: 10.1093/gerona/glv181.
17. Vetrano DL, Foebel AD, Marengoni A, Brandi V, Collamati A, Heckman GA, et al. Chronic diseases and geriatric syndromes: The different weight of comorbidity. Eur J Intern Med. 2016;27:62-7. DOI: 10.1016/j.ejim.2015.10.025.
18. Куликова М.И., Черняева М.С. Влияние полипрагмазии на когнитивные функции пациентов старческого возраста. Медицинский алфавит. 2019;1(3):49-50. Elibrary ID: 37131587
19. Остроумова О.Д., Куликова М.И., Остроумова Т.М., Черняева М.С., Кочетков А.И., Парфенов В.А. Лекарственноиндуцированные когнитивные нарушения. Неврология, нейропсихиатрия, психосоматика. 2020;12(3):11-18. DOI: 10.14412/2074-2711-2020-3-11-18
20. Ильина Е.С., Доскина Е.В., Богова О.Т., Болотокова А.В., Горбатенкова С.В., Головина О.В., и др. Лекарственный аудит, как профилактика падений у пациента старческого возраста. Остеопороз и остеопатии. 2020;23(2):57-58. Elibrary ID: 45432885
21. Ильина Е.С., Шалыгин В.А., Иващенко Д.В., Савельева М.И., Синицина И.И., Семенова Е.П., и др. Падения у коморбидных пациентов старческого возраста при сочетанном применении психотропных и кардиологических лекарственных средств. Нервно-мышечные болезни. 2019;9(1):67-74. DOI: 10.17650/2222-8721-2019-9-1-67-74
22. Maher R.L., Hanlon J., Hajjar E.R. Clinical consequences of polypharmacy in elderly. Expert Opin Drug Saf. 2014;13(1):5765. DOI: 10.1517/14740338.2013.827660.
23. Charlesworth CJ, Smit E, Lee DS, Alramadhan F, Odden MC. Polypharmacy Among Adults Aged 65 Years and Older in the United States: 1988-2010. J Gerontol A Biol Sci Med Sci. 2015;70(8):989-95. DOI: 10.1093/gerona/glv013.
24. Фармакотерапия у лиц пожилого и старческого возраста. Клинические рекомендации МЗ РФ, 2018.
25. Schjøtt J., Andreassen L.M., Dale H., Stokes Ch.L. Review of clinical questions submitted to Norwegian drug information centers concerning administration and dosage to older patients of relevance to patient-centric care. Pharmaceutics. 2021;13(1):105. DOI: 10.3390/pharmaceutics13010105
26. Van der Heyden J, Berete F, Renard F, Vanoverloop J, Devleesschauwer B, De Ridder K, et al. Assessing polypharmacy in the older population: Comparison of a self-reported and prescription based method. Pharmacoepidemiol Drug Saf. 2021;30(12):1716-1726. DOI: 10.1002/pds.5321.
27. Cherubini A, Oristrell J, Pla X, Ruggiero C, Ferretti R, Diestre G, et al. The persistent exclusion of older patients from ongoing clinical trials regarding heart failure. Arch Intern Med. 2011;171(6):550-6. DOI: 10.1001/archinternmed.2011.31.
28. De Almeida AJPO, de Almeida Rezende MS, Dantas SH, de Lima Silva S, de Oliveira JCPL, de Lourdes Assunção Araújo de Azevedo F, et al. Unveiling the Role of Inflammation and Oxidative Stress on Age-Related Cardiovascular Diseases. Oxid Med Cell Longev. 2020;2020:1954398. DOI: 10.1155/2020/1954398.
29. Chinta S.J., Woods G., Rane A., Demaria M., Campisi J., Andersen J.K. Cellular senescence and the aging brain. Exp Gerontol. 2015;68:3-7. DOI: 10.1016/j.exger.2014.09.018
30. Herrera M.D., Mingorance C., Rodríguez-Rodríguez R., Alvarez de Sotomayor M. Endothelial dysfunction and aging: an update. Ageing Res Rev. 2010;9(2):142-152. DOI: 10.1016/j.Arr.2009.07.002
31. Tesauro M., Mauriello A., Rovella V., Annicchiarico-Petruzzel-li M., Cardillo C., Melino G., Di Daniele N. Arterial ageing: from endothelial dysfunction to vascular calcification. J Intern Med. 2017;281(5):471-482. DOI: 10.1111/joim.12605
32. Trindade M., Oigman W., Fritsch Neves M. Potential role of endothelin in early vascular aging. Curr Hypertens Rev. 2017;13(1):33-40. DOI: 10.2174/1573402113666170414165735
33. Neves M.F., Cunha A.R., Cunha M.R., Gismondi R.A., Oigman W. The role of rennin-angiotensin-aldosterone system and its new components in arterial stiffness and vascular aging. High Blood Press Cardiovasc Prev. 2018;25(2):137-145. DOI: 10.1007/s40292-018-0252-5
34. Nusbaum N.J. Aging and sensory senescence. South Med J. 1999;92(3):267-275. DOI: 10.1097/00007611-19990300000002
35. Loh KY, Ogle J. Age related visual impairment in the elderly. Med J Malaysia. 2004;59(4):562-8, quiz 569. PMID: 15779599.
36. Halter J.B., Ouslander J.G., Tinetti M.E., Studenski S., High K.P., Asthana S., eds. Hazzard’s geriatric medicine and gerontology. 6 ed. New York: mcgraw Hill, 2009.
37. Радченко В.Г., Селиверстов П.В. Возрастные изменения печени. Вестник Северо-Западного государственного медицинского университета им. И.И. Мечникова. 2017;9(1):110-116. Elibrary ID: 29024983
38. Mangoni A.A., Jackson Sh. Age-related changes in pharmacokinetics and pharmacodynamics: basic principles and practical applications. Br J Clin Pharmacol. 2004;57(1):6-14. DOI: 10.1046/j.1365-2125.2003.02007.x
39. Klotz U. Pharmacokinetics and drug metabolism in the elderly. Drug Metab Rev. 2009;41(2):67-76. DOI: 10.1080/03602530902722679
40. Turnheim K. When drug therapy gets old: pharmacokineti and pharmacodynamics in the elderly. Exp Gerontol. 2003;38(8):843-853. DOI: 10.1016/s0531-5565(03)00133-5
41. Bowie M.W., Slattum P.W. Pharmacodynamics in older adults: a review. Am J Geriatr Pharmacother. 2007;5(3):263-303. DOI: 10.1016/j.amjopharm.2007.10.001
42. Triflro G., Spina E. Age-related changes in pharmacodynamics: focus on drugs acting on central nervous and cardiovascular systems. Curr Drug Metab. 2011;12(7):611-620. DOI: 10.2174/138920011796504473
43. Cusack B.J., Vestal R.E. Clinical pharmacology: Special considerations in the elderly. In: Calkins E, Davis PJ, Ford AB, eds. Practice of geriatric medicine. Philadelphia: W.B. Saunders Co.; 1986. P. 115-136.
44. Остроумова О.Д., Черняева М.С., Сычев Д.А. Депрескрайбинг антигипертензивных препаратов у пациентов старших возрастных групп. Рациональная Фармакотерапия в Кардиологии. 2020;16(1):82-93. DOI: 10.20996/1819-6446 -2020-02-14
45. Mattappalil A, Mergenhagen KA. Neurotoxicity with antimicrobials in the elderly: a review. Clin Ther. 2014;36(11):14891511.e4. DOI: 10.1016/j.clinthera.2014.09.020.
46. Molinari E, Spatola C, Pietrabissa G, Pagnini F, Castelnuovo G. The Role of Psychogeriatrics in Healthy Living and Active Ageing. Stud Health Technol Inform. 2014;203:122-33. PMID: 26630519.
47. Mangoni A A., Jarmuzewska A E. Incorporating pharmacokinetic data into personalised prescribing for older people: challenges and opportunities. European Geriatric Medicine. 2021;12(3):435-442. DOI: 10.1007/s41999-020-00437-5
48. Lavan A.H., Gallagher P.F., O’Mahony D. Methods to reduce prescribing errors in elderly patients with multimorbidity. Clin Interv Aging. 2016;11:857-866. DOI: 10.2147/CIA.S80280
49. Samaranayake N.R., Layanthi S., Samaraweera D.G.S., Zumara M.S., Nawarathneraja T.S., Hettihewa M., et al. Assessing the appropriateness of medicines among elderly using the, Modified STOP/START criteria for Sri Lanka. 2018.
50. Drug research and development for adults across the older age span: Proceedings of a Workshop. National Academies Press (US), 2021. DOI: 10.17226/2599
Supplementary files
Review
For citations:
Safronenko A.V., Gantsgorn E.V., Safronenko V.A., Kuznetsov I.I., Sukhorukova N.V., Krishtopa A.V., Osipova A.A. Features of pharmacotherapy at elderly and senile patients. South Russian Journal of Therapeutic Practice. 2021;2(4):6-15. (In Russ.) https://doi.org/10.21886/2712-8156-2021-2-4-6-15
Views:
29846
Email this article 